- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2014
- Public Summary Document (PSD) March 2014 PBAC Meeting - PDF
Ranibizumab – March 2014
RANIBIZUMAB, solution for intravitreal injection, 2.3 mg in 0.23 mL, Lucentis®, Novartis Pharmaceuticals Australia Pty Ltd
Last updated
8 November 2023